Search | Clinical Trials Finder

Conditions: Warts, Verruca (Warts), Verruca Vulgaris
Interventions: 9-valent human papillomavirus vaccine, Sterile Saline; Biological · Other
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Postoperative Pain, Hip Arthroscopy
Interventions: Preop PENG block, Placebo block, Ropivacaine 0.5% Injectable Solution, Normal Saline; Procedure · Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Respiratory Syncytial Virus
Interventions: mRNA-1345, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 349 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 47
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Banning, California + 41 more

Conditions: Asthma
Interventions: Magnesium Sulfate, Heptahydrate, 0.9% saline; Drug
Lead sponsor: University of Utah; Other
Eligibility: 2 Years to 17 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Columbus, Ohio • Philadelphia, Pennsylvania • Salt Lake City, Utah

Conditions: Herpes Zoster
Interventions: Live attenuated herpes zoster vaccine, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 3
States / cities: Iowa City, Iowa • Baltimore, Maryland • Nashville, Tennessee

Conditions: Risk Reduction
Interventions: Trivalent Salmonella Conjugate Vaccine (TSCV) Full-Strength Formulation, Trivalent Salmonella Conjugate Vaccine (TSCV) Half-Strength Formulation, Trivalent Salmonella Conjugate Vaccine (TSCV) Dilutional Half-Strength Formulation, Placebo; Biological · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 49 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Botulism Vaccine
Interventions: Placebo (USP sterile saline for injection), rBV A/B-40 vaccine; Biological
Lead sponsor: DynPort Vaccine Company LLC, A GDIT Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 440 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 6
States / cities: Miami, Florida • Pembroke Pines, Florida • Lenexa, Kansas + 3 more

Conditions: Tympanic Membrane Perforation
Interventions: FGF-2, Placebo; Drug · Other
Lead sponsor: D. Bradley Welling, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Boston, Massachusetts • Lackland City, Texas

Conditions: Acute Pain
Interventions: Twin block local anesthetic nerve block using standard dental anesthetic, Twin block with placebo; Drug · Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Posttraumatic Stress Disorder
Interventions: Typhoid Vi Polysaccharide Vaccine, Placebo; Biological
Lead sponsor: University of California, San Francisco; Other
Eligibility: 30 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: San Francisco, California

Conditions: HIV Infections
Interventions: VRC01, SC placebo for VRC01, IV placebo for VRC01; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 6
States / cities: Boston, Massachusetts • New York, New York • Cleveland, Ohio + 1 more

Conditions: SARS-CoV-2 Infection
Interventions: 25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant), Sodium chloride, USP, for injection (0.9% NaCl), 50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant); Biological · Drug
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Infertility of Uterine Origin
Interventions: AMD3100, Normal saline, dilation and curettage; Drug · Procedure
Lead sponsor: Reproductive Medicine Associates of New Jersey; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: San Francisco, California • Basking Ridge, New Jersey • Philadelphia, Pennsylvania

Conditions: HIV-1
Interventions: 3BNC117-LS, 10-1074-LS, Sterile Saline; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Bethesda, Maryland • New York, New York

Conditions: Shigella Infection
Interventions: Placebo, WRSs2, WRSs3; Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: TTR-mediated Amyloidosis, Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Familial Amyloid Polyneuropathies, Amyloid Neuropathies, Amyloidosis, Hereditary, Transthyretin-Related
Interventions: patisiran (ALN-TTR02), Sterile Normal Saline (0.9% NaCl); Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 13
States / cities: La Mesa, California • Orange, California • Denver, Colorado + 9 more

Conditions: Type 1 Diabetes
Interventions: Denosumab, Placebo; Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Birmingham, Alabama • Duarte, California • Indianapolis, Indiana

Conditions: Diabetes Mellitus, Type 2
Interventions: GZR-18, Placebo; Drug · Other
Lead sponsor: Gan and Lee Pharmaceuticals, USA; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Infertility, Infertility, Female, Oocyte Retrieval, Postoperative Pain, Embryo Transfer
Interventions: Ketorolac (Toradol), Placebo (saline); Drug · Other
Lead sponsor: Shady Grove Fertility Reproductive Science Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Rockville, Maryland • Fairfax, Virginia

Conditions: Post Traumatic Stress Disorder (PTSD)
Interventions: Stellate Ganglion Block injection with ropivicane, Placebo Procedure; Procedure
Lead sponsor: United States Naval Medical Center, San Diego; Federal
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: San Diego, California

Conditions: Tibial Meniscus Injuries, Tibial Meniscus Tears, Tibial Meniscus, Torn, Anterior Cruciate Ligament Tear
Interventions: Zilretta, Placebo; Drug · Other
Lead sponsor: Austin V Stone; Other
Eligibility: 18 Years to 40 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Cardiac Surgery, Cardiopulmonary Bypass
Interventions: AT-III (Human), Placebo; Biological · Other
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 41
States / cities: Orange, California • San Francisco, California • Stanford, California + 36 more

Conditions: Pain
Interventions: Placebo Comparator, Active Comparator; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: COVID-19, Coronavirus, Coronavirus Infection
Interventions: Convalescent Plasma, Saline solution; Biological · Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 941 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 9
States / cities: New Haven, Connecticut • Miami, Florida • New York, New York + 5 more

Search by objective public record fields.

Intralesional Gardasil-9 for the Treatment of Recalcitrant Warts

PENG Block for Arthroscopic Hip Surgery

A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus

Timely Intravenous Magnesium for Asthma in Children

ZOSTAVAX® in Renal Transplant Patients

Salmonella Conjugates CVD 2000: Study of Responses to Vaccination With Trivalent Salmonella Conjugate Vaccine to Prevent Invasive Salmonella Disease

Double Blind, Safety and Immunogenicity Study of Recombinant Botulinum Vaccine A/B

Fibroblast Growth Factor Regeneration of Tympanic Membrane Perforations

Twin Block, Pain Medications and Third Molar Extractions

Inflammation and Threat Sensitivity in PTSD

Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults

PHASE 1 SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19

Endometrial Rejuvenation Study

A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy

Safety and Immunogenicity of Two Live, Attenuated Oral Shigella Sonnei Vaccines: WRSs2 and WRSs3

APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis

Denosumab for Type 1 Diabetes

Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy Subjects

Assessing Ketorolac (Toradol) at Oocyte Retrieval

A Randomized, Placebo-Controlled Trial of Stellate Ganglion Block in the Treatment of Post Traumatic Stress Disorder

Success of Long-acting Anti-inflammatories After Anterior Cruciate Ligament and Meniscal Injury

Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass

Use of Dexmedetomidine for Deep Sedation in Patients Undergoing Outpatient Hysteroscopic Surgery

CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients